by Stacey Hawkins | Mar 17, 2016 | Uncategorized
Alzheimer’s Pipeline Roundup Alzheimer’s disease ranks as one of the toughest nuts to crack within drug discovery and development. Current treatments merely manage symptoms, so finding a better solution becomes more and more urgent as the aging population grows.... 
by Stacey Hawkins | Sep 24, 2015 | Oncology
The Metabolics Of Cancer Tackling cancer requires a multi-pronged strategy. Currently, many of the cancer drugs on the market work by inhibiting the signaling pathways that activate cell division. These pathways are often the root cause of cancer—a mutated gene leads... 
by Stacey Hawkins | Sep 2, 2015 | RNA Therapeutics
Newest Hopeful In Cholesterol Lowering Landscape Just weeks after the biotech world celebrated the approvals of two new cholesterol-lowering PCSK9 inhibitors, Regeneron/Sanofi’s Praulent and Amgen’s Repatha, a potential future rival arrived in style.... 
by Stacey Hawkins | May 26, 2015 | Metabolic & Cardiovascular Disease
The Race Against Nash A silent epidemic creeping upon the Western world pushed the headline grabbing acquisition of a Phase 1 non-alcoholic steatohepatitis (NASH) drug last week. Boehringer Ingelheim (Ingelheim, Germany) acquired Pharmaxis (Sydney, Autralia) due to... by Stacey Hawkins | May 13, 2015 | Drug Delivery
A Constant Hurdle in Drug Delivery When it comes to achieving success in drug development, picking the right drug target and developing an effective inhibitor (or activator) is only half the battle. A drug candidate may appear promising in cell-based testing—and even...
